Please wait while we load the requested 10-K report or click the link below:
FOR IMMEDIATE RELEASE
|Sam Brown, Inc. (media)|
Thomas P. Hess, CPA
|Mike Beyer (773) 463-4211|
Vice President, Finance and CFO
ADOLOR CORPORATION REPORTS
YEAR END 2007 FINANCIAL RESULTS
Delta Program Update Provided
EXTON, PA, February 29, 2008 Adolor Corporation (Nasdaq: ADLR) today reported financial results for the year and fourth quarter ended December 31, 2007 and provided an update on its Delta Program.
2007 Financial Results
For the twelve months ended December 31, 2007, the company reported a net loss of $48.4 million or $(1.05) per basic and diluted share, compared to a net loss of $69.7 million, or $(1.56) per basic and diluted share for the same period in 2006. For the three month period ended December 31, 2007, the company reported a net loss of $10.1 million or $(0.22) per basic and diluted share, compared to a net loss of $18.4 million or $(0.40) per basic and diluted share in the three months ended December 31, 2006.
We enter 2008 with two strong lead development programs, increasing momentum in discovery research, and a solid financial foundation, said Michael R. Dougherty, president and chief executive officer of Adolor Corporation. With our PDUFA date for Entereg on May 10, 2008, we await the FDAs completion of its review of our NDA for postoperative ileus. We look ahead to realizing our objective of making this important new product available to patients in the near future.
A highlight of the fourth quarter of 2007 was our collaboration with Pfizer Inc for the Delta Program, continued Dougherty. Pfizer shares our vision for this program, the development of an entirely new class of opioid receptor agonists, and our joint efforts are now well underway. Finally, we are increasingly enthusiastic about our early discovery and research programs, and believe our efforts here will lead to the identification of new development candidates for our growing pipeline.
The following information was filed by Adolor Corp (ADLR) on Friday, February 29, 2008 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Adolor Corp's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Adolor Corp.